Search
Syndax Pharmaceuticals Inc
SNDXAdd to Watchlist
19.241USD
+0.240+1.27%
Market hours （ET）Quotes delayed by 15 min
1.70BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Syndax Pharmaceuticals Inc is 8.86, ranking 44 out of 389 in the Biotechnology & Medical Research industry. The average price target is 38.00, with a high of 56.00 and a low of 27.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
40.000
Target Price
+110.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Syndax Pharmaceuticals Inc
SNDX
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Syndax Pharmaceuticals Inc's expected revenue for the next quarter?
Syndax Pharmaceuticals Inc's expected revenue is 79.33M.
What is Syndax Pharmaceuticals Inc's price target?
Analysts forecast that Syndax Pharmaceuticals Inc's price target is USD 38.00, with the highest forecast at USD 56.00 and the lowest forecast at USD 27.00.
How have Syndax Pharmaceuticals IncSNDX's recent earnings per share performed?
The market expectation was USD -0.48, while Syndax Pharmaceuticals IncSNDX's earnings per share (EPS) for the previous quarter was USD -0.78. EPS for the next quarter is expected at USD -0.48.
What is the analyst rating for Syndax Pharmaceuticals Inc?
Based on the ratings of Syndax Pharmaceuticals Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
